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A B S T R A C T
Objectives: The association between inadequate sleep and type 2 diabetes has garnered much atten-
tion, but little is known about sleep and type 1 diabetes (T1D). Our objectives were to conduct a systematic
review and meta-analysis comparing sleep in persons with and without T1D, and to explore relation-
ships between sleep and glycemic control in T1D.
Methods: Studies were identiﬁed from Medline and Scopus. Studies reporting measures of sleep in T1D
patients and controls, and/or associations between sleep and glycemic control, were selected.
Results: A total of 22 studieswere eligible for themeta-analysis. Childrenwith T1D had shorter sleep duration
(mean difference [MD] = −26.4minutes; 95% conﬁdence interval [CI] = −35.4, −17.7) than controls. Adults with
T1D reported poorer sleep quality (MD in standardized sleep quality score = 0.51; 95% CI = 0.33, 0.70), with
higher scores reﬂecting worse sleep quality) than controls, but there was no difference in self-reported sleep
duration. Adultswith TIDwho reported sleeping >6 hours had lower hemoglobin A1c (HbA1c) levels than those
sleeping ≤6 hours (MD = −0.24%; 95% CI = −0.47, −0.02), and participants reporting good sleep quality had lower
HbA1c than those with poor sleep quality (MD = −0.19%; 95% CI = −0.30, −0.08). The estimated prevalence of
obstructive sleep apnea (OSA) in adults with TID was 51.9% (95% CI = 31.2, 72.6). Patients with moderate-to-
severe OSA had a trend toward higher HbA1c (MD = 0.39%, 95% CI = −0.08, 0.87).
Conclusion: T1D was associated with poorer sleep and high prevalence of OSA. Poor sleep quality, shorter
sleep duration, and OSA were associated with suboptimal glycemic control in T1D patients.
© 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Insuﬃcient sleep duration and poor sleep quality are associ-
ated with insulin resistance, impaired glucose metabolism, and type
2 diabetes (T2D) in both experimental and epidemiological studies
[1,2]. Obstructive sleep apnea (OSA) is also common in patients with
T2D [2], and a greater severity of OSA is associated with greater
insulin resistance [2]. Furthermore, insuﬃcient sleep, poor sleep
quality, and OSA have been associated with poorer glycemic control
among people with T2D [1].
Type 1 diabetes (T1D), although less prevalent than T2D, has been
estimated to affect three million people in the United States [3]. The
incidence varies signiﬁcantly among countries worldwide, with the
lowest among East Asians and American Indians and the highest
among Finnish people [3]. Poor glycemic control in T1D patients can
lead to microvascular complications (ie, nephropathy, retinopa-
thy, and neuropathy), cardiovascular disease, and mortality [4–6].
Despite the abundant evidence linking sleep deﬁciencies and T2D,
little attention has been paid to patients with type 1 diabetes (T1D).
In contrast to T2D, T1D is an autoimmune disorder that results in
destruction of pancreatic β cells and insulin deﬁciency, necessitat-
ing exogenous insulin administration to regulate blood sugars.
Nonetheless, research on T2D may be relevant, as sleep deﬁcien-
cies have been found to be associated with insulin resistance and,
if present in T1D, may result in poorer metabolic control. We hy-
pothesized that sleep deﬁciencies would also be associated with T1D
and suboptimal glycemic control. Therefore, the purpose of this study
was to conduct a systematic review to identify studies in order to
perform meta-analyses comparing sleep characteristics, including
sleep stages, sleep duration, sleep quality, and OSA, between persons
with T1D and healthy controls. In addition, the relationship between
these sleep characteristics and glycemic control in T1D patients was
examined using meta-analyses.
2. Methods
2.1. Data sources and searches
We searched studies published in English from Medline and
Scopus since their inception until May 2015. The search terms and
search strategy were “sleep OR insomnia OR apnea” AND “type 1
diabetes OR autoimmune diabetes OR insulin dependent diabe-
tes”. Reference lists of included studies were examined to identify
additional relevant studies.
2.2. Study selection
Studies published in English were eligible if they met one or both
of the following criteria: compared sleep characteristics (ie, sleep
stages, duration, quality, or OSA) in patients with T1D and
nondiabetes (herein referred to as controls); or assessed the rela-
tionship between sleep characteristics and glycemic control, as
evaluated by hemoglobin A1c (HbA1c), in patients with T1D. HbA1c
is an indicator of glucose control in the preceding 90 days and re-
garded as a gold standard of glycemic measurement. We excluded
studies in pregnant women and studies that induced hypoglyce-
mia. Study selection was performed by two reviewers (S.R. and T.A.).
Disagreements were resolved by a consultation with senior authors
(A.T. and K.L.K.).
Because of the relatively small numbers of studies in some sleep
categories, authors were contacted for additional data. Studies mea-
suring sleep quality via questionnaires had to provide a score in the
same direction to be included in the meta-analyses (ie, studies with
higher score reﬂecting worse sleep were grouped together).
2.3. Sleep characteristics
Sleep stages, expressed as percentage of total sleep time, were
obtained using polysomnography (PSG) in most studies, with the
exception of one study [7] that used a wireless sleep monitor that
recorded electroencephalograms (Zeo Inc, NewtonMA). Stages 1 and
2were combined into “light non-rapid eyemovement (NREM) sleep,”
and stages 3 and 4 (if used) into “deep NREM sleep.” Sleep dura-
tion was obtained either by objective measurements (ie,
polysomnography [PSG], actigraphy, wireless sleep monitor use) or
self-report. Sleep duration was examined as a continuous variable
as well as categorized as shorter (≤6 hours in adults, <9 hours in
children aged 6–13 years, or <8 hours in children aged >13–17 years)
or longer (>6 hours in adults, ≥9 hours in children aged 6−13 years,
or ≥8 hours in children aged >13–17 years) [8]. Objective and sub-
jective assessments of sleep quality were included. Objective
measurements were based on sleep eﬃciency (percentage of time
in bed spent sleeping) obtained from PSG or actigraphy. Good sleep
quality was deﬁned as sleep eﬃciency of ≥85%. Self-reported sleep
quality was assessed by standardized questionnaires, such as Pitts-
burgh Sleep Quality Index (PSQI) [9], Patient Health Questionnaire
(PHQ-9) [10], the Autonomic System Proﬁle (APS) [11], or insom-
nia symptoms [12,13]. Self-reported sleep quality was categorized
as good or poor according to the cutoff of the original question-
naire (eg, PSQI score >5, sleeping diﬃculties per PHQ-9, or insomnia
symptoms). In addition, a total score was used to compare sleep
quality between groups of participants in the studies using PSQI or
APS as described in the data analysis below (higher scores on these
questionnaires reﬂected poorer sleep quality).
The presence of OSA in adults was deﬁned as an apnea–hypopnea
index (AHI) of ≥5 events per hour from PSG or pulse oximetry with
airﬂow measurement that provided AHI values [14], or as having
a pathological oximetry (deﬁned as repetitive desaturation–
reoxygenation sequences) result. Severity of OSA in adults was
categorized as mild for AHI ≥5 to <15, and moderate to severe for
AHI ≥15. In children and adolescents, OSA was deﬁned as AHI ≥1.5
[15]. Studies evaluating OSA risk using a screening questionnaire
(low vs high risk of OSA) [16–18] were also included.
2.4. Glycemic measurements
In addition to using actual HbA1c values, glycemic control was
categorized as optimal (HbA1c <7% in adults, or <7.5% in children)
or suboptimal (HbA1c ≥7% in adults, or ≥7.5% in children) [19].
2.5. Data extraction
Datawere extracted following a standardized data extraction form
(see Supplemental material). Characteristics of the studies that were
extracted included the age group (children/adolescents, adults), mean
bodymass index (BMI), HbA1c, method of sleepmeasurements, sleep
characteristics, and glycemic control. The data pooled for analyses
included the number of participants, mean and standard devia-
tion (SD) for continuous data, and frequency for dichotomous data.
Most authors (88%) of selected articles for which additional data
were not available in publications responded to the communica-
tion [16,17,20–33], and 75% of these authors were able to provide
additional data and were therefore included in the analyses
[16,17,20–29].
2.6. Quality assessment
Quality assessment was performed using the Newcastle–Ottawa
Scale [34]. For case–control studies, three domains were consid-
ered: selection of study groups (four items), comparability of groups
(one item), and ascertainment of exposure (three items). The cohort
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assessment forms were modiﬁed to be applicable for cross-sectional
studies. These consisted of three domains: selection (two items),
comparability (one item), and outcome (one item). Each item was
given one star or no star for all domains except comparability, for
which two stars could be awarded.
2.7. Data synthesis and analysis
The meta-analyses were performed if there were three or more
studies with suﬃcient data for pooling in each planned analysis. If
the number of studies was less than three, they were included in
description in Table A1 and the relevant discussion.
For eligible studies, data were pooled separately by the two anal-
yses of interest: (1) sleep differences between T1D patients and
controls; and (2) the relationship between sleep and glycemic control
in T1D patients. Analyses were stratiﬁed by age (adolescents/
children vs adults). When the age range in a study overlapped
between adolescents and adults, we categorized the study accord-
ing to the mean age of the participants. In addition, objective and
subjective assessments of sleep were analyzed separately.
To compare sleep in T1D patients and controls, mean differ-
ences (MDs) of the sleep measures, including sleep duration and
sleep quality (sleep eﬃciency and sleep questionnaire score),
between T1D patients and controls were estimated across studies.
Nonstandardized mean differences were applied for pooling these
MDs for objective sleep measures, whereas standardized mean dif-
ferences were applied for pooling MDs of the sleep questionnaire
score. If heterogeneity was not present, the ﬁxed-effect model was
applied; otherwise, the random-effect model was applied.
To analyze the relationship between sleep and glycemic control
in T1D patients, MDs and variances of the sleep measures were es-
timated across studies between optimal and suboptimal glycemic
control groups, or the MDs of the HbA1c values were estimated
between sleep groups (ie, good vs poor sleep quality, shorter vs
longer sleep duration, OSA vs non-OSA, and moderate to severe OSA
vs non-OSA). These were then pooled using nonstandardized MDs
as described previously.
Finally, OSA prevalence was estimated from studies of glyce-
mic control in T1D patients. A meta-analysis was then applied to
pool the OSA prevalence across studies using a random-effect model.
Heterogeneity was explored using the Q statistic, and a degree
of heterogeneity was quantiﬁed using the I2 statistic. Heterogene-
ity was considered to be present if the p value from the Q statistic
was <0.1 or the I2 was ≥25%. Publication bias was assessed using
funnel plots and Egger tests. All analyses were performed using
STATA version 13.1 software. A p value of <0.05 was considered to
be statistically signiﬁcant.
3. Results
A total of 741 studies were identiﬁed from searching Medline
and Scopus, and one study was identiﬁed from the reference lists
(Fig. 1). In all, 32 studies met the inclusion criteria and were eligi-
ble for review. Of these, 22 were eligible for meta-analysis. The
remaining ten studies are described in Table A1 because there were
fewer than three studies in each pooling category. In addition, some
sleepmeasures included in the 22 studies were not eligible for meta-
analysis for the same reason and are therefore described in Table A1.
Participants’ characteristics, including those of matched con-
trols (if available), and methods of sleep measurements are listed
in Table 1. Of the studies, ten were case–control, 11 were cross-
sectional, and one was a prospective cohort study.
The quality of the studies included in the meta-analysis was as-
sessed. For case–controls and prospective studies, nine of 11 studies
provided clear deﬁnitions of cases and controls, and seven had good
representativeness of case and controls. All had good comparabil-
ity between case and controls for their matched study designs, and
seven of 11 studies had good ascertainment of exposure. All cross-
sectional studies had good representativeness of subjects and good
ascertainment of outcomes. However, only half had good ascer-
tainment of exposure, and four of 11 had good comparability.
3.1. Sleep in T1D patients and controls
Results of the meta-analyses comparing sleepmeasures between
T1D patients and controls are shown in Table 2.
3.1.1. Sleep duration
Only self-reported sleep duration was available for meta-
analyses in adult samples, and there was no difference in self-
reported sleep duration between T1D patients and controls [12,17,35]
(n = 157 patients and 9951 controls; Fig. 2A). In adolescents/
children [23,40,41], sleep duration from PSGwas signiﬁcantly shorter
in T1D patients (n = 70) than in controls (n = 70) (MD = −26.6minutes,
95% CI = −35.4, −17.7; Fig. 2B).
3.1.2. Sleep quality
In adults, sleep quality based on sleep eﬃciency from PSG did
not differ between T1D patients and controls [20,21,35] (n = 52 pa-
tients and 45 controls; Fig. 3A); however, when sleep was assessed
using questionnaires, sleep quality (continuous score) was signiﬁ-
cantly worse in T1D patients compared to controls [17,43,44] (MD
in standardized sleep quality scorewas 0.51, 95% CI 0.33, 0.70; n = 416
patients and 669 controls; Fig. 3B). However, self-reported good sleep
quality did not differ signiﬁcantly in T1D patients (odds ratio [OR]
0.79, 95% CI 0.41, 1.52) compared to control participants [12,13,17]
(n = 277 patients, 61,269 controls; Fig. 3C).
3.2. Sleep and glycemic control
A summary of the analyses of the association between sleep and
glycemic control in T1D patients is presented in Table 3.
3.2.1. Sleep stages
Five adult studies were included in the analysis of sleep stages
[7,20,21,24,29] (n = 36 vs 81 for optimal vs suboptimal glycemic
control). In adults, those with optimal glycemic control (HbA1c <7%)
spent less time in light NREM sleep (pooled MD = −2.90%, 95%
CI = −6.96, 1.16) and more time in deep NREM sleep (pooled
MD = 2.95%, 95% CI = −1.98, 7.88) than those with suboptimal gly-
cemic control (HbA1c ≥ 7%), but it was not statistically signiﬁcant
(Fig. A1).
3.2.2. Sleep duration
In adults, HbA1c levels did not differ signiﬁcantly between those
who slept >6 hours compared to ≤6 hours based on objective sleep
measurements in six studies [7,16,20,21,24,29] (n = 127 vs 68;
Fig. A2A). However, in four adult studies [17,25–27] those who re-
ported sleeping >6 hours had a signiﬁcantly lower HbA1c level
(−0.24%, 95% CI = −0.47, −0.02) compared to those reporting sleep-
ing for ≤6 hours (n = 381 vs 152). In four adult studies [17,25−27],
patients with optimal glycemic control (<7%) reported sleeping an
average of 17.3 minutes more (95% CI = 4.13, 30.37) compared to
those with suboptimal glycemic control (≥7%; n = 138 vs 397), but
the objective sleep duration analyzed in six adult studies
[7,16,20,21,24,29] (n = 54 vs 142) did not differ based on optimal (<7%)
vs suboptimal control (≥7%), with a pooled MD of −2.88 minutes
(95% CI = −18.09, 12.34) (Fig. A2B).
Meta-analysis of two child studies with four cohorts [22,26] re-
vealed no signiﬁcant differences in HbA1c levels in combined age
groups between those who reported longer vs shorter sleep dura-
tion (n = 96 vs 35; Fig. A3A). The subanalysis by age groups revealed
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no signiﬁcant difference in HbA1c levels between those reported
sleeping ≥9 vs <9 hours in children aged 6–13 years. There was a
trend toward lower HbA1c, albeit not statistically signiﬁcant, in those
reported sleeping ≥8 vs <8 hours in the age group >13–17 years
(MD = −0.97%, 95% CI = −2.22, 0.29). In addition, mean sleep dura-
tion by questionnaire in combined age groups [22,26] also did not
differ signiﬁcantly between those with optimal and suboptimal gly-
cemic control (pooledMD = 18.6minutes, 95% CI = −12.6, 49.8; n = 32
vs 99; Fig. A3B). The subanalysis by age groups revealed no signif-
icant differences in self-reported sleep duration between those with
optimal vs suboptimal glycemic control in children aged 6–13 years.
Among children aged >13–17 years, those with optimal glycemic
control tended to report longer sleep duration, but this was not sta-
tistically signiﬁcant (MD = 48 minutes; −3.99).
3.2.3. Sleep quality
In four adult studies, HbA1c levels did not differ between those
with good (≥85%) and poor (<85%) sleep quality, based on objec-
tive measurements [16,20,24,29] (n = 86 vs 80; Fig. A4A). Similarly,
there were no differences in sleep eﬃciency between participants
with optimal and suboptimal glycemic control in ﬁve adult studies
[16,20,21,24,29] (n = 48 vs 133; Fig. A4B). However, in three adult
studies, participants with good self-reported sleep quality had sig-
niﬁcantly lower HbA1c levels than those with poor sleep quality
[10,17] (MD = −0.19%, 95% CI = −0.30, −0.08; n = 442 vs 136; Fig. A4A).
3.2.4. OSA
Among adult T1D patients, the prevalence of OSA (deﬁned as AHI
≥5 or pathological oximetry ﬁndings) was 51.9% (95% CI = 31.2, 72.6)
and moderate to severe OSA (AHI ≥15) was 16.7% (95% CI = 1.1, 34.5)
in four studies (n = 186) [20,24,28,29]. Themean difference in HbA1c
levels between adult T1D patients with and without objectively de-
termined OSA was not different in four studies [20,24,28,29] (n = 96
vs 81, Fig. A5A). However, there was a trend toward higher HbA1c
levels when comparing those with moderate–severe OSA (AHI ≥15)
to those without OSA (AHI <5) in three studies [24,28,29] (n = 47
Q
Fig. 1. Flow chart of study selection. Poolings were performed when there were three or more studies in the same category.
29S. Reutrakul et al. / Sleep Medicine 23 (2016) 26–45
Table 1
Characteristics of the studies and their sleep variables included in the meta-analyses.
Study Setting T1D participants Control participants Study design Sleep measurement Sleep characteristics in
meta-analyses
N Age (y) BMI (kg/m2) HbA1c (%) N Age (y) BMI (kg/m2)
Studies comparing sleep in type 1 diabetes vs control participants
Barone et al. [35] Brazil 18 26.3 23.0 7.8 9 28.8 22.0 Matched case–control
(age, BMI)
Sleep diary, actimeter, PSGc Duration, quality
Janovsky et al. [20] Brazil 20 28.6 22.9 7.2 22 23.2 21.8 Matched case–control
(age, BMI)
PSGa Stages, duration,
quality, OSA
Jauch-Chara et al. [21] Germany 14 31.3 24.2 7.7 14 28.9 23.1 Matched case–control
(age, BMI, sex)
PSGb Stages, duration,
quality
Mandl et al. [43] Sweden 31 52.0 23.9 NA 200 45.0 24.4 Unmatched case–
control
Questionnaire (8 sleep questions from
Autonomic Symptom Proﬁle)
Quality
Matyka et al. [40] UK 15 9.4 8.8 15 9.2 Matched case–control
(age, sex)
PSGa Duration
Olsson et al. [13] Norway 138 54.3 29.2 NA 51050 43.0 24.8 Prospective study,
mean follow up 15.3 y
Questionnaire of insomnia symptoms Quality
Palladino et al. [44] USA 117 18.5 25.7 8.9 122 18.0 Case–control Questionnaire (ﬁrst ﬁve questions of PSQI) Quality
Perfect et al. [23] USA 50 13.4 67.6 percentile 9.1 40 13.5 65.8 percentile Matched case–control
(age, BMI, sex)
PSGc (40 matched pairs)
Actigraphyc (diabetes cohort)
Duration
Pillar et al. [41] Israel 15 12.6 18.5 8.5 15 13.3 19.3 Matched case–control
(age, BMI)
PSGc Stages, duration,
quality
Sivertsen et al. [12] Norway 40 19.9 233.2 NA 9843 19.9 22.2 Unmatched case–
control
Questionnaire (sleep duration, insomnia
symptoms, snoring)
Duration, quality
van Dijk et al. [17] The Netherlands 99 43.9 24.5 7.8 99 44.1 24.5 Matched case–control
(age, BMI, sex)
Questionnaires (PSQI and OSA risk) Duration, quality
Studies exploring the relationship between sleep and glycemic control in type 1 diabetes patients
Bachle et al. [45] Germany 202 19.4 23.7 8.3 Cross-sectional Questionnaire (Patient Health
Questionnaire, PHQ-9, sleeping diﬃculties)
Quality
Borel et al. [24] France 37 43.0 24.9 7.8 Cross-sectional Oximetrya (N = 37)
PSGa (N = 18)
Stages, duration,
quality, OSA
Borel et al. [16] France 79 39.5 24.5 7.9 Cross-sectional Actigraphya
Questionnaire evaluating OSA risk
Duration, quality, OSA
Bot et al. [10] The Netherlands 277 43.9 25.4 7.8 Cross-sectional Questionnaire (Patient Health
Questionnaire, PHQ-9, sleeping diﬃculties)
Quality
Bouhassira et al. [25] France 297 48.3 25.4 7.9 Cross-sectional Questionnaire (Medical Outcome Sleep
Scale assessing sleep quantity and
disturbances)
Duration
Estrada et al. [26], ages
6–13
USA 36 9.8 BMI z-score −1.11 8.3 Cross-sectional Questionnaire Duration
Estrada et al. [26], ages
>13–17
USA 50 15.1 BMI z-score −0.40 9.5 Cross-sectional Questionnaire Duration
Estrada et al. [26],
adults
USA 20 25.9 29.7 8.6 Cross-sectional Questionnaire Duration
Feupe et al. [7] USA 17 19–26 NA 7.3 Cross-sectional Wireless sleep monitorsc Stages, duration
Manin et al. [29] France 67 54.0 25.8 7.6 Cross-sectional PSGa (N = 54)
PSGa (N = 13)
Stages, duration,
quality, OSA
Matejko et al. [27] Poland 148 26.3 23.3 7.2 Cross-sectional Questionnaire (Self-reported sleep
duration)
Duration
Perfect [22], ages 10–
13
USA 24 11.5 BMI z-score 0.36 8.2 Cross-sectional Questionnaire (Self-reported sleep
duration)
Duration
Perfect [22], ages >13–
17
USA 26 15.2 BMI z-score 0.88 9.7 Cross-sectional Questionnaire (Self-reported sleep
duration)
Duration
Schober et al. [28] Germany 62 41.7 25.5 8.1 Cross-sectional Apnea linka (pulse oximetry and air ﬂow
measurement)
OSA
Abbreviations: BMI, body mass index; OSA, obstructive sleep apnea; PSG, polysomnography; T1D, type 1 diabetes.
a Recordings performed without glucose measurements.
b Recordings performed under nonhypoglycemic condition.
c Recordings performed with glucose measurements. Some participants had hypoglycemia.
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Table 2
Meta-analyses of mean difference (MD) of sleep characteristics between type 1 diabetes (T1D) patients and control participants.
Sleep characteristics Sleep measurements Population No. of studies T1D (n) Controls (n) Resultsa
Sleep duration (min) Questionnaire Adults 3 157 9,951 No differences in sleep duration
(MD = −0.73 min, 95% CI = −14.35, 12.89)a
PSG Adolescents/children 3 70 70 T1D patients had shorter sleep duration by
−26.55 min (95% CI = −35.39, −17.70).
Sleep eﬃciency (%)b PSG Adults 3 52 45 No differences in sleep eﬃciency, MD = 0.70%
(95% CI = −1.28, 2.68)
Sleep quality Questionnaire (questionnaire
score)c
Adults 3 416 669 T1D patients had poorer sleep quality
(standardized MD = 0.51, 95% CI = 0.33, 0.70)
Questionnaire (dichotomized
good vs poor sleep quality)
Adults 3 277 61,269 No differences in self-reported good sleep
quality between T1Dand controls (OR = 0.79,
95% CI = 0.41, 1.52)
Abbreviations: CI, conﬁdence interval; OR, odds ratio; PSG, polysomnography.
a Calculated by sleep variables of T1D patients minus those of control participants unless otherwise noted.
b Higher number reﬂecting better sleep quality.
c Higher number reﬂecting poorer sleep quality.
Fig. 2. Mean difference in sleep duration between patients with type 1 diabetes (T1D) and controls (calculated by sleep duration in minutes of T1D patients minus that of
controls). (A) Adults by questionnaire. (B) Adolescents/children by polysomnography.
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Fig. 3. Comparisons of sleep quality between patients with type 1 diabetes (T1D) and controls. (A) Mean difference in sleep eﬃciency by polysomnography (PSG) (sleep
eﬃciency of T1D patients minus that of controls). (B) Standardized mean difference in sleep quality score by questionnaire with higher score reﬂecting worse quality (T1D
patient score minus that of controls). (C) Association between T1D and good sleep quality.
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Table 3
Meta-analyses of the relationship between sleep and glycemic control in patients with type 1 diabetes (T1D).
Sleep variables Analysis Sleep measurements Studies (n) N Type of participants Resultsa
Sleep stages MD in percentages of sleep stages between
those with optimal and suboptimal
glycemic controlsb
PSG, wireless sleep monitor 5 36 vs 81 Adults No differences in light sleep, MD = −2.90%, (95%
CI = −6.96, 1.16).
36 vs 81 No differences in deep sleep, MD = 2.95%, 95%
CI = −1.98, 7.88
Sleep duration MD in HbA1c levels between those with
longer and shorter sleep durationsc
PSG, wireless sleep monitor or actigraphy 6 127 vs 68 Adults No differences in HbA1c, MD = 0.03%, −0.43,
0.49
Questionnaire 4 381 vs 152 Adults Those with longer sleep duration had lower
HbA1c, MD −0.24%, 95% CI = −0.47, −0.02.
Questionnaire 4 96 vs 35 Adolescents/children No differences in HbA1c in all combined age
groups, MD = −0.07%, 95% CI =−0.52, 0.39; age
6–13, MD = 0.07%, 95% CI = −0.42, 0.55; and age
>13–17, MD = −0.97%, 95% CI = −2.22, 0.29
MD in sleep duration between those with
optimal and suboptimal glycemic controlsb
PSG, wireless sleep monitor, or actigraphy 6 54 vs 142 Adults No differences in sleep duration,
MD = −2.88 min, 95% CI = −18.09, 12.34
Questionnaire 4 138 vs 397 Adults Those with optimal glycemic control had
longer sleep duration, MD = 17.28 min, 95%
CI = 4.13, 30.370.
Questionnaire 4 35 vs 104 Adolescents/children No difference in sleep duration in all combined
age groups, MD = 18.6 min, 95% CI = −12.6,
49.8; age 6–13, MD = 0.6 min, 95% CI = −39.0,
40.2; and age >13–17, MD = 48 min, 95%
CI = −3.0, 99.0
Sleep qualityd MD in HbA1c levels between those with
good and poor sleep qualitye
PSG or actigraphy 4 86 vs 80 Adults No differences in HbA1c, MD = 0.01%, 95%
CI = −0.35, 0.36
Questionnaire 3 442 vs 136 Adults Those with good sleep quality had lower
HbA1c, MD 95% CI = −0.19%, −0.30, −0.08.
MD in sleep qualityd between those with
optimal and suboptimal glycemic controlb
PSG or actigraphy 5 48 vs 133 Adults No differences in sleep eﬃciency, MD = −0.11%,
95% CI = −1.69, 1.47
OSA MD in HbA1c levels between those with
and without OSAf
PSG or oximetry 4 96 vs 81 Adults No difference in HbA1c, MD = 0.17%, 95%
CI = −0.22, 0.57
MD in HbA1c levels between those with
moderate−severe OSA and without OSAf
PSG 3 47 vs 69 Adults No statistically signiﬁcant differences in
HbA1c, MD = 0.39%, −0.08, 0.87
MD in AHI between those with optimal
and suboptimal glycemic controlsb
PSG 4 53 vs 114 Adults Those with optimal glycemic control had lower
AHI, MD = −2.95 events/h, 95% CI = −5.69, −0.21.
Abbreviations: AHI, apnea–hypopnea index; MD, mean difference; OSA, obstructive sleep apnea; PSG, polysomnography.
a Calculated by sleep variables of patients with optimal glycemic control minus those of patients with suboptimal glycemic control, or HbA1c of patients with good sleep minus HbA1c of patients with poor sleep, unless
otherwise noted.
b Optimal glycemic control is deﬁned as HbA1c <7% in adults or <7.5% in children, and suboptimal glycemic control is deﬁned as HbA1c ≥7% in adults or ≥7.5% in children, with the exception of the study by Villa et al. [42], in
which optimal glycemic control was deﬁned as HbA1c <8%.
c Longer sleep duration is deﬁned as sleep duration of >6 hours in adults or >8 hours in children, and shorter sleep duration is deﬁned as sleep duration ≤6 hours in adults or ≤8 hours in children.
d Measured as sleep eﬃciency by PSG or actigraphy, or sleep quality score per the sleep questionnaires.
e Good sleep quality is deﬁned as sleep eﬃciency ≥85% as measured by PSG or actigraphy or per the cutoff of the sleep questionnaire; poor sleep quality is deﬁned as sleep eﬃciency <85% as measured by PSG or actigraphy
or per the cutoff of the original sleep questionnaire.
f Obstructive sleep apnea (OSA) is deﬁned as AHI ≥5 as measured by PSG or oximetry or having pathological oximetry readings; moderate to severe OSA is deﬁned as AHI ≥15.
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vs 69), with a pooled MD of 0.39% (95% CI = −0.08, 0.87; Fig. A5B).
In addition, the AHI in T1D patients was compared between those
with optimal and suboptimal glycemic controls in four adult studies
[20,24,28,29] (n = 53 vs 114). Participants with optimal glycemic
control had signiﬁcantly lower AHI than those with suboptimal gly-
cemic control (MD = −2.95 events per hour, 95% CI = −5.69, −0.21;
Fig. A5C). There were not enough studies in children to examine OSA
and T1D.
3.3. Publication bias
Funnel plots and Egger tests, where applicable, were used to
assess asymmetry of the funnel and small-study effect for all pooling
(Figs. A6 and A7 and Table A2). Of all the 19 poolings, 17 showed
no evidence of asymmetry, and only two poolings showed asym-
metry (association between objectivelymeasured sleep duration and
glycemic control in adults, and objectively measured sleep quality
and glycemic control in adults). Egger tests indicated small-study
effects (Table A2). The reason for this was further explored using
contour-enhanced funnel plots. These suggested that studies with
lower precision showed higher negative MDs (ie, lower sleep
duration/quality in optimal than suboptimal glycemic control) than
studies with higher precision (Fig. A7), suggesting a publication bias
for these two poolings.
4. Discussion
The results of these meta-analyses indicate some signiﬁcant dif-
ferences in sleep characteristics between persons with and without
T1D. In comparison to control participants, adults with T1D had
worse sleep quality, especially when assessed by questionnaires. Un-
fortunately, there were too few studies using PSG to compare sleep
architecture between T1D and controls. Although there was no dif-
ference in sleep duration in adults with andwithout T1D, youth with
T1D slept signiﬁcantly less than controls. However, we found an as-
sociation between glycemic control and sleep duration or quality
in adults. Shorter self-reported sleep duration and poor self-
reported sleep quality were associated with suboptimal glycemic
control. Finally, we found that the prevalence of OSA in adults with
T1D is strikingly high (51.9%) and approaches that of type 2 dia-
betes (54%–86%) [1], despite average BMI values below 30 kg/m2.
In addition, patients with suboptimal glycemic control had more
sleep apnea as reﬂected by higher AHI in adults, and similar ﬁnd-
ings were reported in child studies. Overall, these results suggest
an important relationship between sleep and T1D.
In the present analyses, the adult T1D patients with optimal gly-
cemic control spent less time in light NREM sleep and more time
in deep NREM sleep, suggesting that worse glycemic control might
be associated with shallower sleep, although the difference did not
reach statistical signiﬁcance. A study of adolescents with T1D found
that more time spent in N3 was associated with better glycemic
control [23]. Physiologically, N3 is associated with less sympathet-
ic nervous system activity and is thought to be a “restorative” stage
of sleep, which could explain the association with better glycemic
control [46].
Our analysis did not ﬁnd differences in sleep duration between
adult patients with T1D and controls. However, children with T1D
slept an average of 26 minutes, by objective measurement, less than
controls. The reason for the discrepancy between age groups is
unclear, but could be due to the small number of studies analyzed
or different glycemic conditions during the PSG recordings. A ques-
tionnaire study of 323 persons including patients with T1D and their
ﬁrst- and second-degree relatives found that 41% had insuﬃcient
sleep based on the American Academy of Sleep Medicine recom-
mendations (<10 hours for those aged 5–11, <9 hours for those aged
12−19 years, and <7 hours for those aged 20 years), although com-
parisons with control subjects were not performed [26]. Having T1D
itself could possibly affect time spent in bed or sleep duration due
to nocturnal hypoglycemia disrupting sleep and the need for night-
time diabetes care.
Among adults with T1D, the meta-analysis revealed a relation-
ship between self-reported sleep duration and glycemic control. The
average HbA1c level was 0.24% lower among those who reported
sleeping for >6 hours. Although six hours of sleep may not be suf-
ﬁcient [47], the aggregated available data did not allow us to re-
categorize sleep duration inmore detail. Similarly, thosewith optimal
glycemic control reported sleeping 17minutes more on average than
patients with suboptimal glycemic control. The trend was similar
in the studies of children, especially in the age group of >13–17 years,
although not statistically signiﬁcant. Objectively measured sleep du-
ration was not related to glycemic control in one child study [23]
and most of the adult studies. One limitation of these analyses is
that sleep duration estimated from PSG does not represent habit-
ual behavior. One study in adults that used actigraphy, which better
represents habitual sleep duration, revealed that HbA1c levels were
signiﬁcantly higher in those with shorter sleep duration (<6.5 hours)
compared to those who slept for >6.5 hours (8.5% vs 7.7%) [16]. Col-
lectively, these data suggest that there is an association between
better glycemic control and longer sleep duration in T1D patients.
Consistent with this, one-night experimental sleep restriction to four
hours in bed in seven T1D patients was associated with decreased
peripheral insulin sensitivity, compared to a night with normal sleep
duration (average of 7.8 hours) [38]. This agrees with several ex-
perimental studies in healthy volunteers that showed impaired
glucose tolerance after sleep restriction [48,49]. Whether sleep ex-
tension in T1D patients with short sleep will lead to improvement
in glycemic control remains the subject of future research.
We found that sleep quality scores as assessed by question-
naire were worse in adults with T1D compared to controls, although
the questionnaires used differed among studies. The proportion of
participants with self-reported good sleep quality, however, did not
differ between the two groups. There was only one prospective study
suggesting that sleep disturbance was a risk factor for developing
autoimmune diabetes [13]. Although the mechanism was not ex-
plored, the author postulated that sleeping diﬃculty may contribute
to increased insulin resistance that could facilitate diabetes onset
in susceptible individuals [13]. In the current analysis, adult pa-
tients with T1D with self-reported, but not objectively measured,
good sleep quality had a signiﬁcantly lower HbA1c by 0.19%. In ad-
dition, a longitudinal study in type 1 patients found that sleeping
diﬃculties, reported in 21% of participants, were signiﬁcantly related
to higher HbA1c values at one-year follow-up [10]. The discrepan-
cy between objective and subjective measure of sleep quality may
be due to methodological differences. Objective sleep quality was
represented by sleep eﬃciency from a single night of PSG, whereas
subjective reports were based on the previous month. In addition,
the number of participants who had PSG in the current analysis was
relatively small. Sleep quality in T1D could be impaired by many
factors, including neuropathic pain [25], hypoglycemia, which may
result in increased carbohydrate consumption the followingmorning
[50], disrupted sleep, and psychological factors, which are all as-
sociated with suboptimal glycemic control [51,52]. In healthy adult
volunteers, experimental sleep disruption resulted in an in-
creased insulin resistance in healthy individuals [51]. Whether poor
sleep quality is associated with insulin resistance in T1D patients
is unknown.
Although no differences in AHI were found between T1D pa-
tients and controls in two small studies [20,35], and although OSA
symptoms were not consistently different when assessed by ques-
tionnaires [12,17], our results revealed a high prevalence of OSA in
adult T1D patients from four larger studies (51.9%), as assessed by
objective sleepmeasurements (oximetry or PSG). This is much higher
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than that in the general population, which is estimated to be 3%–
7% and increases with age and obesity [53]. Mean BMI values of the
participants in our analysis were between 22.9 and 25.8 kg/m2, so
obesity alone could not explain the high prevalence. Studies have
suggested that the presence of neuropathy, especially autonomic
neuropathy, may compromise upper airway reﬂexes and control of
the pharyngeal muscle, predisposing the patients to obstructive
events [54]. A small previous study found that neuropathy was
common in T1D patients with apnea [55]. PSG data in 20 T1D pa-
tients revealed a signiﬁcantly higher prevalence of OSA in those with
cardio-autonomic neuropathy than in T1D patients without this con-
dition (67% vs 23%) [20]. These data support the role of neuropathy
and an increased OSA risk in these patients. Finally, as OSA is known
to be associated with disturbed sleep duration and quality, the pres-
ence of OSAmay also be partly responsible for the ﬁndings on sleep
duration and quality in our analyses.
The present analyses found that the presence of OSA in adults,
especially moderate to severe OSA, may be associated with worse
glycemic control, although the association did not reach statistical
signiﬁcance. In addition, adults with optimal glycemic control had
signiﬁcantly lower AHI than those with suboptimal glycemic control,
and similar ﬁndings were reported in child studies, although there
were not enough to be pooled for meta-analysis [23,42]. Although
the mechanism linking OSA to suboptimal glycemic control has not
been explored speciﬁcally in T1D patients, reduced insulin sensi-
tivity may play a role as suggested by studies that experimentally
induced intermittent hypoxia in healthy volunteers [56,57]. Thus,
the presence of OSA, which is highly prevalent in T1D, may ad-
versely affect glycemic control in these patients. One study also found
that the presence of OSA in T1D patients was associated with car-
diovascular disease and retinopathy [29], which resembles the
ﬁndings in those with type 2 diabetes. There are currently no data
exploring the effect of OSA treatment on glycemic control or com-
plications in patients with T1D.
The inclusion of common sleep disturbances and exploration of
their relationship with glycemic control in T1D population is the
strength of this study. Additional data obtained from authors, mostly
unpublished, also contributed to the strength of our analyses. Still,
the primary limitation of these analyses is the small number of
studies available, which limited our statistical power and in-
creased the likelihood of type 2 error. This underscores the
importance of more research on sleep in T1D patients. A second lim-
itation is that almost all studies were cross-sectional, precluding the
assumption of causality. Indeed, impaired sleep could affect glyce-
mic control, but suboptimally controlled glucose levels could also
impair sleep. Third, some patients experienced hypoglycemia during
the single-night PSG recording, which could not be controlled for
in our analyses [23]. Hypoglycemia has been known to affect sleep
architecture [58] and sleep eﬃciency [41]. However, the occur-
rence of hypoglycemia is common in T1D, and therefore not
excluding patients who experience hypoglycemia is more reﬂec-
tive of real-world experiences. It is also important to note that the
magnitude of HbA1c differences in those with and without sleep
disturbances is relatively small, although it is comparable to some
of the standard and advanced therapies for T1D patients, such as
carbohydrate counting [59], or the use of continuous subcutane-
ous insulin infusion [60]. In addition, none of the studies speciﬁcally
excluded participants with anemia or certain hemoglobinopa-
thies that could potentially affect HbA1c measurements. Finally,
summary data analysis does not allow adjustments for factors related
to glycemic control such as therapy adherence or assessments of
hypoglycemia. Future studies should include a larger number of par-
ticipants and should use consistent multi-day, multi-informant, and
multi-methods to prospectively and longitudinally assess sleep.
5. Conclusion
In summary, the interactions between sleep and type 1 diabe-
tes are complex and likely bidirectional. Type 1 diabetes is associated
with poor sleep quality and a high prevalence of OSA. Sleep dis-
turbances, including poor sleep quality, shorter sleep duration, and
OSA, are associatedwith suboptimal glycemic control. Whether sleep
optimization will improve glycemic control is a subject of future
research. More research is clearly needed to understand the rela-
tionship between sleep and glycemic control in type 1 diabetes
patients.
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Appendix A
Table A1
Qualitative review of additional studies and sleep variables not eligible for meta-analysis.
Study T1D/controls (n) Population Study design Sleep
measurement
Sleep variables Results
Barone et al.
[35]
18/9 Adult Matched case–control
(age, BMI)
Sleep diary, actimeter, PSGd Stages,
duration,
quality, OSA
No differences in percentage of sleep stages in control vs T1D participants: REM sleep (21.5% vs 19.9%,
p = 0.62) or stage 3 (21.7% vs 20.6%, p = 0.76)
Mean sleep duration from sleep diaries and nightly rest duration as assessed by actimeter were not
correlated with mean glucose level as assessed by CGM.b However, in a subgroup of patients with low
glycemia (mean glucose ≤154 mg/dL) (n = 9), nightly rest period negatively correlated with mean
glycemia (r = −0.89, p = 0.03).
Sleep quality as assessed by visual analogue scale did not correlate with mean glycemia as measured
by CGM. In a subgroup of patients with low glycemia, sleep quality negatively correlated with mean
glycemia.
No differences in mean AHI (control vs T1D patients, 2.9 vs 3.4). None of the participants had OSA. In
T1D, there was a correlation between AHI and mean glucose level (r = −0.55, p = 0.03), and arousal
index and mean glucose level by CGM (r = 0.56, p = 0.03).
Blanz et al.
[36]
93/93 Children/
adolescents
Unmatched case–
control
Interview as a part of
psychiatric assessments
(sleep disturbances)
Quality More T1D reported sleep disturbances than control participants (χ2 test, 8.08, p < 0.01)
Borel et al.
[16]
79/NA Adults Cross-sectional Questionnaire evaluating
OSA risk
OSA Mean HbA1c was similar between those who reported snoring and those who did not snore
(7.9% ± 1.0% vs 7.9% ± 1.1%, p = 0.89) (personal communication).
Caruso et al.
[37]
49/36 Children/
adolescents
Unmatched case–
control
Questionnaire (Sleep
Disturbance Scale for
Children [SDSC])
Quality T1D had signiﬁcantly lower sleep quality than control participants (higher SDSC score). These
included the total score (control vs T1D 43.8 vs 63.1, p < 0.001), disorders of initiating and maintaining
sleep (55.0 vs 68.5, p < 0.001), disorders of sleep–wake transition (49.2 vs 57.1, p < 0.005) and
disorders of excessive somnolence (48.5 vs 61.4, p < 0.001). No signiﬁcant differences in the subscale
of disorders of arousal, sleep hyperhidrosis, and sleep-disordered breathing between the two groups.
Donga et al.
[38]
7/NA Adults Intervention study Experimental sleep
restriction
Sleep duration Sleep restriction for one night (4 h) resulted in a signiﬁcantly decreased glucose disposal rate during
hyperinsulinemic euglycemic clamp (reﬂecting decreased insulin sensitivity) compared to a night
with normal sleep duration (average 7.8 h).
Happe et al.
[39]
46/50 Children/
adolescents
Sibling study Questionnaire Quality,
snoring,
restless legs
syndrome
No differences between T1D and control participants in percentages with restless legs syndrome
symptoms (2.2% vs 2.0%), sleep initiation problem (10.9% vs 4.0%), sleep maintenance problem (6.5%
vs 4.0%), or snoring (13.0% vs 14.0%)
Janovsky
et al. [20]
20/22 Adults Matched case–control
(age, BMI)
PSGa Stages,
duration, OSA
No differences in percentage of sleep stages in control vs T1D participants: stage 1 (3.2% vs 4.5%), stage
2 (58.5% vs 57.8%), stage 3 (21.6% vs 21.2%) (personal communication).
Sleep duration was similar between control participants vs T1D patients without CAN vs T1D without
CAN (416 vs 379 vs 359 min)
Mean AHI was similar between control participants vs those with T1D (3.7 vs 4.5). 40% of T1D vs 4.5%
of control participants had OSA.T1D patients with CAN had signiﬁcantly higher AHI than T1D patients
without CAN (6.4 vs 3.2).
Jauch-Chara
et al. [21]
14/14 Adults Matched case–control
(age, BMI, sex)
PSGc Stages,
duration
No differences in percentage of sleep stage 1 (controls vs T1D patients 19.2% vs 14.2%, p = 0.34), slow-
wave sleep (controls vs T1D patients 14.9% vs 14.7%, p = 0.75). T1D patients spent more time in stage 2
than control participants (55.2% vs 47.2%, p = 0.01). During the ﬁrst half of the night, there was a trend
toward less time spent in slow-wave sleep in T1D patients than in controls (21.3% vs 24.7%, p = 0.09).
Sleep duration was similar between the two groups (404 min vs 395 min, p = 0.93)
Kilmek et al.
[30]
16,667/
1,845,591
All ages Cross-sectional,
population based
Nationwide claims data on
sleep disorders diagnosis
(G47)
All sleep
disorders in
G47 diagnosis
code
Sleep disorders were more commonly comorbid in T1D patients (relative risk = 1.9, 95% CI = 1.5–2.4).
Low et al.
[11]
83/245 Adults Matched case–control,
comparable age and
sex
Questionnaire (eight sleep
questions from Autonomic
Symptom Proﬁle)
Quality T1D patients had poorer sleep quality than controls (mean score = 0.27 vs 0.07; higher score reﬂects
poorer sleep), but this was not statistically signiﬁcant.
(continued on next page)
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Table A1 (continued)
Study T1D/controls (n) Population Study design Sleep measurement Sleep variables Results
Matyka et al.
[40]
15/15 Children/
adolescents
Matched case–control
(age, sex)
PSGa Stages, quality No signiﬁcant differences in percentage of sleep stages between controls and T1D patients (stage 1:
4.3% vs 4.9%, p = 0.1; stage 2: 24.5% vs 22.7%, p = 0.7; stage 3: 51.4% vs 50.5%, p = 0.8) or REM sleep
(17.8% vs 15.7%, p = 0.2).
Compared to non-hypoglycemic night, the recordings during hypoglycemia revealed more time spent
in slow wave sleep (60.4% vs 38.9%, p = 0.04) and less time in REM sleep (11.5% vs 15.2%, p = 0.04).
T1D spent more time in short wake (<2 min) and long wake (>2 min) than controls (median 0.8% vs
0%, and 1.2% vs 0%, respectively)
Perfect et al.
[23]
50/40 Children/
adolescents
Matched case–control
(age, BMI, sex)
PSGd (40 matched pairs)
Actigraphyd (T1D cohort)
Stages,
duration,
quality, OSA
Compared to controls, T1D spent more time in stage 2 (57.2% vs 52.3%, p < 0.01) and less time in stage
3 (14.5% vs 18.9%, p < 0.05). More time spent in stage 2 was associated with higher HbA1c values and
mean glucose levels by 5-day CGM.
Sleep duration was not related to glucose control. Sleep duration each night was not related to waking
glucose levels.
No differences in sleep eﬃciency between T1D and control participants (86.6% vs 85.9%). Sleep
eﬃciency was not related to glucose control.
OSA prevalence and mean AHI were similar in T1D and control participants (35% vs 28%, and 2.48 vs
2.20), but central apnea index was higher in T1D patients than in controls (1.44 vs 0.33, p < 0.05). T1D
patients with OSA (AHI ≥1.5) had signiﬁcantly higher glucose levels by 5-day CGM than those without
OSA. In addition, those with optimal glycemic control (n = 6) (HbA1c <7.5%) had lower AHI than those
with suboptimal glycemic control (n = 34) (0.67 ± 0.49 vs 2.79 ± 4.64) (personal communication).
Perfect [22] 50/NA Children/
adolescent
Cross-sectional Questionnaire (School
Sleep Habit Survey)
Quality Sleep quality was worse (as reﬂected by a lower score) in patients with suboptimal glycemic control
(HbA1c ≥7.5%) than those with optimal glycemic control (7.8 ± 2.1, n = 42 vs 8.7 ± 1.3, n = 7). In
addition, patients with suboptimal glycemic control had more daytime sleepiness (higher score) than
those with optimal glycemic control (7.7 ± 3.5, n = 42 vs 5.2 ± 1.7, n = 7) (personal communication).
Pillar et al.
[41]
15/15 Children/
adolescents
Matched case–control
(age, BMI)
PSGc Stages, quality No differences in percentage of sleep stage 3 (control vs T1D 25% vs 23%) or REM sleep (20% vs 20%).
However, when analyzing only T1D with hypoglycemia during the recordings, T1D spent more time in
stage 3 than controls (29% vs 25%, p < 0.05).
No differences in sleep eﬃciency between the two groups. However, when analyzing only T1D with
hypoglycemia, sleep eﬃciency increased compared to that in controls (95% vs 92%, p < 0.05)
Sivertsen
et al. [12]
40/9843 Adults Unmatched case–
control
Questionnaire Quality, OSA No differences in sleep eﬃciency (as calculated from self-reported sleep timing and sleep latency)
between control and T1D participants (85% vs 87%, p = 0.57)
No differences in frequency of snoring and report of sleepiness at least three times/wk between
control and T1D participants (4.1% vs 6.9%, p = 0.16)
Sturrock and
Moriarty
[31]
300/143 Adults Unmatched case–
control
Questionnaire (Nottingham
Health Proﬁle, sleep, NHP
category)
Quality T1D patients had worse sleep quality than control participants as reﬂected by a higher NHP sleep
score (12.2 vs 9.3, p < 0.01)
van Dijk
et al. [17]
99/99 Adults Matched case–control
(age, BMI, sex)
Questionnaires (OSA risk) OSA More T1D patients were at high risk for OSA compared to controls (17.2% vs 5.1%, p = 0.01). No
association between OSA risk and suboptimal glycemic control (HbA1c ≥7.5%), OR = 0.50 (0.15–1.59),
p = 0.24.
Varni et al.
[33]
83/157 Children/
adolescents
Unmatched case–
control
Questionnaire (PedsQL
Multidimensional Fatigue
Scale)
Sleep quality T1D had signiﬁcantly worse sleep/rest fatigue score (as reﬂected by lower score) than control
participants (69.3 vs 77.4, p < 0.05).
Villa et al.
[42]
25/20 Children/
adolescents
Matched case–control
(age)
PSGa OSA Apnea index was higher in T1D than control participants (2.62 vs 1.40, p = 0.006). Central apnea index
was higher in T1D with HbA1c ≥8% than control participants (2.54 vs 0.78, p < 0.0001), and tended to
be higher in T1D patients with HbA1c <8% than in control participants (1.34 vs 0.78, p = 0.07).
T1D patients with optimal glycemic control (n = 12) (HbA1c ≤7.9%) had a nonsigniﬁcant lower apnea
index than those with suboptimal glycemic control (n = 11) (2.03 ± 1.78 vs 3.28 ± 1.64) and a
signiﬁcantly lower central apnea index (1.34 ± 1.29 vs 2.54 vs 1.27, p = 0.03).
Yeshayahu
and
Mahmud
[32]
75/54 Children/
adolescent
Unmatched case–
control
Questionnaire Duration Mean sleep duration during weekdays was longer in T1D than in control participants (8.4 vs 8.0 h,
p = 0.01), and both groups had longer sleep durations on weekends (an increase by 1.8 and 2.2 h in
T1D and control participants, respectively).
Mean sleep times or wake times in T1D patients did not differ based on HbA1c levels.
Abbreviations: AHI, apnea–hypopnea index; BMI, body mass index; CAN, cardiac autonomic neuropathy; CGM, continuous glucose monitor; OR, odds ratio; OSA, obstructive sleep apnea; PSG, polysomnography; REM, rapid eye
movement; T1D, type 1 diabetes.
a Recordings performed without glucose measurements.
b Recordings performed with continuous glucose monitor.
c Recordings performed under non-hypoglycemic conditions.
d Recordings performed with glucose measurements. Some participants had hypoglycemia. 37
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Fig. A1. Relationship between sleep stages and glycemic control in type 1 diabetes (T1D) patients. (A) Mean difference of percentages of sleep time spent in light sleep
between participants with optimal (HbA1c <7%) and suboptimal (HbA1c ≥7%) glycemic control (GC) (calculated by percentage of sleep time of participants with optimal GC
minus those with suboptimal GC). (B) Mean difference of percentages of sleep time spent in deep sleep between those with optimal and suboptimal GCs. NREM, non-rapid
eye movement; REM, rapid eye movement.
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Fig. A2. Relationship between sleep duration and glycemic control (GC) in adults with type 1 diabetes (T1D). (A) Mean difference in HbA1c levels between participants
with longer sleep duration (>6 hours) and those with shorter sleep duration (≤6 hours). (B) Mean difference in sleep duration between participants with optimal (HbA1c
<7%) and suboptimal (HbA1c ≥7%) GCs (calculated by sleep duration in minutes of those with optimal GC minus those with suboptimal GC). PSG, polysomnography.
39S. Reutrakul et al. / Sleep Medicine 23 (2016) 26–45
Fig. A3. Relationship between sleep duration and glycemic control (GC) in children with type 1 diabetes (T1D). (A) Mean difference in HbA1c levels between participants
with longer and shorter sleep durations, calculated by HbA1c in those with longer sleep duration minus that of those with shorter sleep duration. (B) Mean difference in
sleep duration between participants with optimal (HbA1c < 7.5–8%) and suboptimal (HbA1c ≥ 7.5–8%) GCs.
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Fig. A4. Relationship between sleep quality and glycemic control (GC) in adults with type 1 diabetes (T1D). (A) Mean difference in HbA1c levels between participants with
good sleep quality (sleep eﬃciency ≥85% as measured by polysomnography [PSG] or actigraphy, or per sleep quality score cutoff according to the sleep questionnaire used)
and those with poor sleep quality. (B) Mean difference in sleep eﬃciency between participants with optimal (HbA1c <7%) and suboptimal (HbA1c ≥7%) GCs.
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Fig. A5. Relationship between obstructive sleep apnea (OSA) and glycemic control (GC) in patients with type 1 diabetes (TID). (A) Mean difference in HbA1c levels between
participants with OSA and without OSA in adults (calculated by HbA1c in those with OSA minus those without OSA). (B) Mean difference in HbA1c levels between those
with moderate to severe OSA (AHI ≥15) and those without OSA (AHI <5) in adults (calculated by HbA1c in those with moderate to severe OSA minus those without OSA).
(C) Mean difference in AHI between those with optimal (HbA1c < 7%) and suboptimal (HbA1c ≥ 7%) GCs (calculated by AHI of those with optimal GC minus those with sub-
optimal GC).
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Fig. A6. Funnel plots of the mean difference between patients with type 1 diabetes (T1D) and control participants. (A) Sleep duration. (B) Sleep quality.
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Fig. A7. Funnel and contour-enhanced funnel plots for mean differences between adult type 1 diabetes (T1D) patients with good and poor glycemic controls. (A) Sleep du-
ration as obtained by objective measurements. (B) Sleep quality by objective measurements.
Table A2
Small-study effects in the relationship between sleep characteristics and glycemic control.
Sleep variables Analysis Sleep measures No. of
studies
Type of subjects Egger test
Sleep stages MD in percentage of sleep stages
between optimal and suboptimal
glycemic controls
PSG, wireless sleep monitor 5 Adults β = −2.45, SE = 2.70, p = 0.432
β = 2.72, SE = 2.33 , p = 0.328
Sleep duration MD in HbA1c between longer and
shorter sleep durations
PSG, wireless sleep monitor or actigraphy 6 Adults β = 0.53, SE = 0.59, p = 0.392
Questionnaire 4 Adults β = 0.74, SE = 1.42, p = 0.655
Questionnaire 3 Adolescents/children β = −3.22, SE = 5.33, p = 0.654
MD in sleep duration between optimal
and suboptimal glycemic control
PSG, wireless sleep monitor or actigraphy 6 Adults β = −2.32, SE = 0.83, p = 0.048
Questionnaire 4 Adults β = −0.70, SE = 0.57, p = 0.348
Questionnaire 4 Adolescents/children β = 11.674, SE = 4.605, p = 0.239
Sleep quality MD in HbA1c levels between good and
poor sleep quality
PSG or actigraphy 4 Adults β = −0.43, SE = 0.19, p = 0.149
Questionnaire 3 Adults β = −1.03, SE = 0.864, p = 0.445
MD in sleep quality between optimal
and suboptimal glycemic controls
PSG or actigraphy 5 Adults β = −1.28, SE = 0.27, p = 0.018
OSA MD in HbA1c levels between OSA and
non-OSA
PSG or oximetry 4 Adults β = −1.38, SE = 1.56, p = 0.468
MD in HbA1c levels between
moderate–severe OSA and non-OSA
PSG 3 Adults β = 0.59, SE = 1.75, p = 0.791
MD in AHI between optimal and
suboptimal glycemic controls
PSG 4 Adults β = −1.32, SE = 1.03, p = 0.330
Abbreviations: AHI, apnea−hypopnea index; MD, mean difference; OSA, obstructive sleep apnea; PSG, polysomnography.
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Appendix B: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.sleep.2016.03.019.
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